Loading ChartRhythms
Preparing market rhythm analysis...
Preparing market rhythm analysis...
Full Rhythm Report
JNJ • Stock • Health Care / Pharmaceuticals
Current Price
$256.03
-1.02%
Provider quote snapshot • As of 2026-10-02T20:00:00.000Z
Back to stock pageCross-Horizon Read
JNJ's evidence points supportive across the available windows.
Generated 2026-10-05T11:30:00.000Z • Evidence c0618679
Price Data
A quote snapshot is available, but historical price data is not connected yet.
ChartRhythms displays a price chart only when real historical time-series data is available. No estimated or synthetic chart is shown.
0–3 days
Supporting articles
0
Opposing articles
0
Neutral articles
0
Confidence basis
Supporting evidence
No supporting articles were found in this window.
Opposing evidence
No opposing articles were found in this window.
Catalysts
No specific catalysts were identified in this window.
Risks
No specific risk mentions were identified in this window.
Next proof points
• Additional dated, company-specific coverage in the 0–3 days window.
Strengthens if
• Supporting evidence (0) grows relative to opposing evidence (0) in this window.
• No evidence is available for this window is resolved.
Weakens if
• Opposing evidence (0) grows relative to supporting evidence (0) in this window.
Sources in this window (0)
No sources are available for this window yet.
4–21 days
Supporting articles
0
Opposing articles
0
Neutral articles
0
Confidence basis
Supporting evidence
No supporting articles were found in this window.
Opposing evidence
No opposing articles were found in this window.
Catalysts
No specific catalysts were identified in this window.
Risks
No specific risk mentions were identified in this window.
Next proof points
22–90 days
The 22–90 days evidence set currently reads bullish.
Supporting articles
7
Opposing articles
2
Neutral articles
6
Confidence basis
Supporting evidence
• Johnson & Johnson (JNJ) On Strong Results And 2026 Outlook Why Valuation Is Back In Focus
• Johnson & Johnson (JNJ) Advances Seltorexant And Expands Outpatient Cardiac Care
• What Johnson & Johnson (JNJ)'s OTTAVA FDA Win and Talc Deal Shift Mean For Shareholders
• Can Johnson & Johnson (JNJ) Challenge Intuitive Surgical (ISRG) After Ottava’s FDA Approval?
Help improve this analysis
This feedback is saved locally for the MVP. Later, ChartRhythms can use this feedback to improve the strategy engine.
Important:
ChartRhythms provides source-based market summaries for research and informational purposes only. This is not financial advice and not a recommendation to buy, sell, or hold any security.
• Additional dated, company-specific coverage in the 4–21 days window.
Strengthens if
• Supporting evidence (0) grows relative to opposing evidence (0) in this window.
• No evidence is available for this window is resolved.
Weakens if
• Opposing evidence (0) grows relative to supporting evidence (0) in this window.
Sources in this window (0)
No sources are available for this window yet.
• Johnson & Johnson (JNJ) Stock Sees Modest Fair Value Lift After Analyst Target Increases
Opposing evidence
• Johnson & Johnson (JNJ) Wins EU Approval For TECVAYLI Combo In Multiple Myeloma
• Johnson & Johnson (JNJ) Registers a Bigger Fall Than the Market: Important Facts to Note
Catalysts
• Johnson & Johnson (JNJ) Stock Sees Modest Fair Value Lift After Analyst Target Increases
Risks
• Johnson & Johnson (JNJ) On Strong Results And 2026 Outlook Why Valuation Is Back In Focus
• Johnson & Johnson (JNJ) Seeks $5.5 Billion Talc Lawsuit Settlement
• Johnson & Johnson (JNJ) Stock May Be 31% Undervalued As Myeloma Trial Results Impress
Next proof points
• Continued coverage in the 22–90 days window confirming the current read.
Strengthens if
• Supporting evidence (7) grows relative to opposing evidence (2) in this window.
Weakens if
• Opposing evidence (2) grows relative to supporting evidence (7) in this window.
Showing 8 of 15 sources
Johnson & Johnson (JNJ) Wins EU Approval For TECVAYLI Combo In Multiple Myeloma
Yahoo • 2026-08-23 • Bearish
Open via Finnhub →Johnson & Johnson (JNJ) Registers a Bigger Fall Than the Market: Important Facts to Note
Yahoo • 2026-08-20 • Bearish
Open via Finnhub →Johnson & Johnson (JNJ) On Strong Results And 2026 Outlook Why Valuation Is Back In Focus
Yahoo • 2026-08-20 • Bullish
Open via Finnhub →Johnson & Johnson (NYSE:JNJ): A Dividend Quality Standout
ChartMill • 2026-08-17 • Neutral
Open via Finnhub →Johnson & Johnson (JNJ)’s $5.5B Talc Settlement: Turning Point or Temporary Relief?
Yahoo • 2026-08-13 • Neutral
Open via Finnhub →Johnson & Johnson (JNJ) Advances Seltorexant And Expands Outpatient Cardiac Care
Yahoo • 2026-08-12 • Bullish
Open via Finnhub →What Johnson & Johnson (JNJ)'s OTTAVA FDA Win and Talc Deal Shift Mean For Shareholders
Yahoo • 2026-08-11 • Bullish
Open via Finnhub →